Ziagen Hypersensitivity Safety Card Will Be Included In Patient Labeling
Executive Summary
Glaxo Wellcome plans to distribute a wallet-card describing hypersensitivity reactions to the nucleoside analog Ziagen (abacavir) as part of its marketing of the drug, the company told FDA's Antiviral Drugs Advisory Committee Nov. 2.